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Background: The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the
EGFR antibodies cetuximab and panitumumab are approved for the treatment of patients with colorectal cancer. However, a
major clinical challenge is a short-term response owing to development of acquired resistance during the course of the treatment.
Methods: In this study, we investigated the molecular mechanisms underlying development of acquired resistance in DiFi
colorectal cancer cells to the anti-EGFR mAb ICR62 (termed DiFi62) and to the small molecule tyrosine kinase inhibitor (TKI)
gefitinib (termed DiFiG) using a range of techniques.
Results: Compared with the findings from parental DiFi and DiFiG cells, development of acquired resistance to anti-EGFR mAb
ICR62 in DiFi62 cells was accompanied by an increase in cell surface EGFR and increased phosphorylation of HER-2 and HER-3.
Interestingly, DiFi62 cells also acquired resistance to treatment with anti-EGFR mAbs cetuximab and ICR61, which bind to other
distinct epitopes on the extracellular domain of EGFR, but these cells remained equally sensitive as the parental cells to treatment
with pan-HER inhibitors such as afatinib.
Conclusions: Our results provide a novel mechanistic insight into the development of acquired resistance to EGFR antibody-
based therapy in colorectal cancer cells and justify further investigations on the therapeutic benefits of pan-HER family inhibitors in
the treatment of colorectal cancer patients once acquired resistance to EGFR antibody-based therapy is developed.
The epidermal growth factor receptor (EGFR/erbB1) is a trans-
membrane glycoprotein and belongs to the erbB family of
receptors, which consists of three other members, HER-2 (erbB2/
Neu), HER-3 (erbB3) and HER-4 (erbB4) (Carpenter, 1987; Haley
et al, 1987; Arteaga and Engelman, 2014). Activation of the EGFR
following the binding of EGFR ligand or EGFR mutation, results in
the activation of several downstream signalling cascades such as
RAS/RAF/MAPK, PI3K/Akt, PLCU/PKC, Src and STAT. This
ultimately contributes to the hallmarks of human cancer via
tumour cell proliferation, reduced apoptosis and increased
migration and invasion (Brand et al, 2011; Hanahan and
Weinberg, 2011; Garouniatis et al, 2012; Khelwatty et al, 2013).
The aberrant expression and activation of the EGFR have been
reported in a wide range of human cancers. This has been
associated with tumour progression and poor survival in many
patients, including those with colorectal cancer (Kluftinger et al,
1992; Mayer et al, 1993; Modjtahedi and Dean, 1994; Spano et al,
2005; Galizia et al, 2006; Khelwatty et al, 2014). The prominent
role of EGFR in the survival and progression of human cancer has
made targeting of the EGFR with mAbs or TKIs an important
therapeutic approach (Sato et al, 1983; Modjtahedi et al, 1993a;
Khelwatty et al, 2013; Okada et al, 2014). Currently, of the anti-
EGFR mAbs, only cetuximab and panitumumab have been
approved for the treatment of patients with metastatic colorectal
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cancer (Wong, 2005; Wu et al, 2008; Modjtahedi et al, 2012;
Arteaga and Engelman, 2014). Although the clinical efficacy of
cetuximab and panitumumab has been demonstrated in many
patients, the duration of response can be short, with rapid
emergence of acquired resistance as a major cause of treatment
failure (Cunningham et al, 2004; Douillard et al, 2010; Elez et al,
2010; Gravalos et al, 2010; Osumi et al, 2013). It is therefore
essential not only to unravel the possible mechanisms of acquired
resistance to therapy with anti-EGFR mAbs in colorectal cancer
but also to develop novel and more effective therapeutic strategies
for such patients (Lu et al, 2007; Yonesaka et al, 2011; Montagut
et al, 2012; Khelwatty et al, 2013).
In the early 1990s, we developed a large panel of anti-EGFR
antibodies against the extracellular domain of the EGFR for use in
cancer therapy (Modjtahedi et al, 1993a, b, 2003; Modjtahedi and
Dean, 1994). Of these, antibody ICR62 was studied extensively due
to its superior anti-tumour activity against the EGFR over-
expressing tumour cells both in vitro and in vivo and clinical
trials have also been conducted with mAb ICR62, and one of the
humanised version of this antibody imgatuzumab (GA201)
(Modjtahedi et al, 1993b, 1996; Modjtahedi and Dean, 1994;
Paz-Ares et al, 2011; Delord et al, 2014). Previously, we reported
that the EGFR-overexpressing DiFi colorectal cancer cells (wild
type for KRAS, BRAF and PI3K) are dependent upon EGFR-
mediated cell signalling for proliferation and survival and that
blockade of the EGFR by anti-EGFR mAb ICR62 or cetuximab, or
inhibition of EGFR with EGFR TKIs leads to cell death via
apoptosis (Wu et al, 1995; Liu and Fan, 2001; Liu et al, 2001;
Cunningham et al, 2006; Khelwatty et al, 2011). In addition, we
and others have shown DiFi colorectal cancer cells to be highly
sensitive to treatment with a panel of our in-house anti-EGFR
mAbs including ICR61, which bind to another epitope on the
extracellular domain of the EGFR distinct from the ICR62 binding
site (Fan et al, 1993; Modjtahedi et al, 1993b). In this study, we
investigated the mechanisms of acquired resistance to therapy with
anti-EGFR mAb ICR62 by treating DiFi cells with chronic doses of
ICR62 or the EGFR TKI gefitinib. We characterised molecular
profiling of parental DiFi cells and their ICR62 and gefitinib-
resistant sublines. We show that tumour cells that acquire
resistance to anti-EGFR mAb ICR62 also acquire resistance to
treatment with mAbs cetuximab and ICR61, both of which bind to
other distinct epitopes on the extracellular domain of the EGFR,
but interestingly, these cells remain sensitive to pan-HER family
inhibitors. In addition, we found that acquired resistance is
accompanied by an increased level of cell surface EGFR and
increased phosphorylation of HER-2 and HER-3.
MATERIALS AND METHODS
Antibodies and other reagents. The rat mAb ICR10 (IgG2a) was
raised against the external domain of the EGFR on the head and
neck carcinoma cell line HN5, and mAbs ICR62 (IgG2b) and
ICR61 (IgG2b) were raised against two other distinct epitopes on
the external domains of the human EGFR on the breast carcinoma
cell line (MDA-MB468) as described previously (Modjtahedi et al,
1993b). The anti-EGFR mAb cetuximab was purchased from
Merck Serono (London, UK). The irreversible pan-HER inhibitor
afatinib (BIBW2992) was kindly provided by Boehringer Ingleheim
(Vienna, Austria). The reversible anti-EGFR TKI, gefitinib (Iressa/
ZD1839) was purchased from R&D Systems (Oxford, UK). A panel
of small molecule TKIs, neratinib, sapitinib, imatinib, dasatinib,
canertinib and lapatinib, was purchased from Stratech Scientific
Ltd (Newmarket, UK) and crizotinib and PF04217903 mesylate
was purchased from R&D systems. Mouse antibodies against
phospho-Tyr-100 and b-actin and rabbit antibodies against total
Akt, MAPK, phospho-MAPK (Thr202/Tyr204), phospho-Akt
(Ser473), anti-phospho EGFR antibodies, anti-phospho HER-2
and HER-3 antibodies were obtained from New England Biolabs
(Hitchin, UK). Mouse anti-EGFR (F4) antibody was purchased
from Sigma-Aldrich (Gillingham, UK).
Tumour cell lines and establishment of variants resistant to
EGFR inhibitors. The human colorectal tumour cell line, DiFi,
was established from a patient with familial adenomatous polyposis
(FAP) as described previously (Fan et al, 1993). All the cell lines
were routinely cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine
serum (FBS; Sigma-Aldrich) and the antibiotics, penicillin,
streptomycin and neomycin (Sigma-Aldrich) and maintained at
37 1C in a humidified atmosphere with 5% CO2. DiFi variant
sublines were established following chronic treatment of DiFi cells
with increasing concentrations of mAb ICR62 (DiFi62) or the
EGFR TKI gefitinib (DiFiG) over a period of 6–10 months. In
parallel, the DiFi parental cells were kept in culture until the
resistant variants were established. The identity of DiFi parental
cells was authenticated using Short Tandem Repeat (STR) profiling
less than 6 months ago (LGC, London, UK).
Growth response studies. The effect of other anti-EGFR mAbs
and small molecule TKIs on the growth of human colorectal
tumour-resistant variant cell lines vs the parental cell line was
investigated using sulphorodhamine B (SRB; Sigma Aldrich)
colorimetric assay as described previously (Khelwatty et al,
2011). Briefly, tumour cells were seeded at a density of 5 103
cells per well in 100 ml growth medium supplemented with 10%
FBS in a 96-well plate. Cells were incubated at 37 1C until the cells
in the wells containing only control medium were near confluent.
The cells were then fixed with 10% trichloroacetic acid (TCA) and
stained with 0.04% SRB in 1% acetic acid and solubilised with
10mM Tris-base and the absorbance of each well was measured
at 565 nm using an Epoch plate reader (Thermo Fisher,
Loughborough, UK). Data were analysed using Gen5 (Biotek,
Swindon, UK) and Calcusyn software (Biosoft, Cambridge, UK).
Flow cytometry. Expression level of the HER family members was
determined by flow cytometry as described previously (Khelwatty
et al, 2011). Briefly, 1 106 tumour cells in 1ml of PBS were
incubated with primary antibodies or control medium for 1 h by
rotation at 4 1C, followed by incubation with FITC-conjugated IgG
secondary antibody for 1 h at 4 1C. A minimum of 10 000 events
were recorded by excitation with an argon laser at 488 nm, and
analysed using the FL-1 detector (FITC detector; 525 nm) of BD
FACScalibur flow cytometer (Becton-Dickinson, Oxford, UK)
using CellQuest Pro software.
Immunofluorescent staining of EGFR. Tumour cells were grown
to near confluence in DMEM/10% FBS in a Lab-Tek Parmanox
eight-well chamber culture slide (VWR, East Grinstead, UK). The
cells were incubated with anti-EGFR antibodies for 1 h on ice or
37 1C (for internalisation studies) and then fixed with 4%
paraformaldehyde for 10min at room temperature. Cell mem-
branes were permeabilised with 0.5% Triton X-100 (Sigma-
Aldrich) in PBS/1% BSA for 20min at room temperature and
blocked with PBS/3% BSA for 30min. The tumour cells were then
incubated with FITC conjugated secondary antibody (AbD Serotec,
Oxford, UK) for 1 h at 4 1C. Following washes in PBS, cells were
incubated with 1mgml 1 of Hoescht 33258 nuclear stain (Sigma-
Aldrich) for 5min at room temperature and mounted with H-1000
mounting medium (Vector Laboratories, Peterborough, UK), cover
slipped (VWR) and photographed using FITC filter array on a
Nikon eclipse i80 fluorescent microscope.
Western blotting. Tumour cells were grown to near confluence in
six-well culture plates (Fisher Scientific, Loughborough, UK)
containing 5ml of 10% FBS/DMEM growth medium. The cells
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were lysed using lysis buffer (Fisher Scientific) containing a
protease inhibitor cocktail (Sigma-Aldrich). The cell lysates were
heated in SDS sample buffer for 10min at 72 1C. Protein samples
were separated on 4–12% Bis-Tris gels (Fisher Scientific) using the
XCell II Surelock Mini-Cell system (Fisher Scientific) and
transferred onto polyvinylidene difluoride (PVDF) membranes.
The PVDF membranes were probed sequentially as described
previously (Cunningham et al, 2006). The specific signals were
detected using G:BOX-CHEMI-XT4 gel documentation system
(Syngene, Cambridge, UK).
Receptor tyrosine kinase proteome array. To determine the
phosphorylation status of human receptor tyrosine kinases (RTKs),
we used the Proteome Profiler 96 purchased from R&D systems.
Cells grown in culture flasks (25 cm2) under normal conditions to
near confluence were lysed at a density of 1 107 cellsml 1. The
proteome array assay was carried out according to the manufac-
turers’ manual. The data were analysed using G:BOX-CHEMI-XT4
and ImageJ software.
DNA sequencing analysis. For DNA sequencing, DNA extraction
from DiFi parental and drug-resistant variants was performed
using the AllPrep DNA/RNA/Protein Mini kit (Qiagen,
Manchester, UK) as described in the manufacturer’s manual.
Sequencing libraries were prepared with 10 ng of each sample using
ready-to-use primers from Ion Ampliseq Cancer Hotspot Panel v2
and Ion Ampliseq Library Kit following manufacturer’s instruc-
tions (Life Technologies, Paisley, UK). Following library prepara-
tion, Ion OneTouch system was used to prepare a template and
sequencing was performed using an Ion 316 chip on an Ion PGM
sequencer and results were analysed using Ion Ampliseq CHPv2
regions and hotspots, hg19 as reference in single sample analysis.
In addition, analysis was also carried out by comparing DiFi
parental (normal) and DiFi drug-resistant variants (tumour) in
paired analysis using Ion Reporter software (Life Technologies).
RESULTS
Resistance to anti-EGFR mAb ICR62 is accompanied with
up-regulation of EGFR. Both ICR62 and gefitinib inhibited the
growth of parental DiFi cells with IC50 values of 1 nM and 25 nM,
respectively (Table 1). To elucidate the molecular mechanisms
underlying the acquired resistance to anti-EGFR therapy, we
chronically exposed parental DiFi cells to increasing concentra-
tions of anti-EGFR mAb ICR62 or the reversible anti-EGFR TKI
gefitinib for a period of 6–10 months. As shown in Figure 1A and
B, both DiFi62 and DiFiG resistant variants acquired resistance to
treatment with ICR62 and gefitinib, with increased IC50 values
being 4209.96 nM for ICR62 and 113.74 nM for gefitinib,
respectively (Table 1).
Following the establishment of the DiFi-resistant variants, we
performed comparative analysis measuring the cell surface
expression of all known members of the erbB family in the
DiFi parental cells and resistant variants DiFi62 and DiFiG.
Interestingly, while the cell surface expression of the HER-2, HER-
3 and HER-4 remained mostly unchanged, there was a marked
increase in the expression of EGFR in DiFi62 variant cells
(Figure 1C). To determine whether the increase in the cell surface
expression of the EGFR was associated with the total EGFR levels,
we determined the total EGFR levels in the DiFi parental and drug-
resistant variants, DiFi62 and DiFiG. Interestingly, western blot
analysis showed that while total EGFR protein was detected
abundantly in the DiFi parental cells and DiFiG resistant
variant, the level of total EGFR in DiFi62 cells was undetectable
using the mouse anti-EGFR (F4) antibody, which is directed
against the intracellular domain of the EGFR (residues 985 to 996)
(Figure 1D). In addition, the result of immunofluorescence staining
with mAb F4 indicated that although it can bind to the EGFR on
DiFi parental cells, it was unable to detect the EGFR in DiFi62
variant cells (Figure 1D). However, subsequent re-probing of the
same membrane using the rat anti-EGFR (ICR10) antibody, which
is directed against the extracellular domain of the EGFR, revealed a
marked increase in the level of EGFR in DiFi62 cells compared to
the level of EGFR in DiFi parental cells and in DiFiG resistant
variant, consistent with the findings of the flow cytometry
(Figure 1C and D). Interestingly, the band detected by anti-EGFR
mAb ICR10 was found to be a ‘fast-migrating’ form of the EGFR
(Figure 1D). These finding suggested that chronic treatment of
DiFi cells with anti-EGFR mAb ICR62 was indeed accompanied by
the appearance of a modified EGFR.
Up-regulation of EGFR in DiFi62 cells is owing to impaired
endocytosis of the EGFR. Considering the lack of detectable total
EGFR protein by western blotting using the mouse anti-EGFR (F4)
antibody, which is directed against the intracellular domain of the
EGFR (Figure 1D), we wondered whether the phosphorylation
status of the EGFR at several sites has altered in DiFi62 cells.
Strikingly, among the listed EGFR phosphorylation sites, phos-
photyrosine was either undetectable or markedly diminished in
DiFi62 cells compared with the findings in parental DiFi or DiFiG
Table 1. Sensitivity of DiFi parental colorectal cancer cells compared with DiFi62 and DiFiG drug-resistant variants to a panel of
mAbs and TKIs as IC50 values (nM)
IC50(nM)
Inhibitors DiFi DiFi62 DiFiG
mAbs
ICR61 (anti-EGFR mAb) 2.19 4209.96 4209.96
ICR62 (anti-EGFR mAb) 1.09 4209.96 3.12
Cetuximab (anti-EGFR mAb) o1.00 4209.96 1.16
Small molecule TKIs
Afatinib (irreversible pan-HER inhibitor) 10.00 8.00 61.00
Canertinib (irreversible pan-HER inhibitor) 4.66 o1.00 89.65
Neratinib (irreversible pan-HER inhibitor) 8.35 1.82 50.65
Sapitinib (equipotent reversible pan-HER inhibitor) 1.44 o1.00 8.29
Lapatinib (reversible dual EGFR and HER-2 inhibitor) 41.55 46.07 374.29
Gefitinib (reversible EGFR inhibitor) 24.98 17.16 113.74
Imatinib (BCR-Abl inhibitor) 41049.80 41049.80 41049.80
Dasatinib (dual Bcr-Abl and Src inhibitor) 41049.80 41049.80 41049.80
PF04217903 mesylate (Alk inhibitor) 41049.80 41049.80 41049.80
Crizotinib (dual cMet and Alk inhibitor) 587.54 488.11 916.76
Abbreviations: EGFR¼ epidermal growth factor receptor; mAb¼monoclonal antibody; TKI¼ tyrosine kinase inhibitor.
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cells (Figure 1E). For example, the phosphorylation of tyrosine
residues 1045 (a Cbl-binding site) was undetectable and the
phosphorylation of tyrosine residues 1068 (a growth factor
receptor binding protein-2-binding site) was significantly reduced
in DiFi62 drug-resistant variant cells, respectively. In contrast,
DiFiG cells retained similar levels of EGFR phosphorylation found
in parental DiFi cells, except the level on Thr-669 residue (ligand-
induced regulation of receptor internalisation; Figure 1E). Using
immunofluorescence staining, we further found that EGFR
remained in the extracellular membrane upon treatment with
ICR62 or cetuximab in the DiFi62 cells compared with reduced
immunofluorescence staining of EGFR in parental DiFi and DiFiG
cells after the same treatment (Figure 1F).
Taken together, these results indicate that the intracellular
cytoplasmic domain of the EGFR in DiFi62 cells is altered and the
increased level of EGFR in DiFi62 cell surface could be a
consequence of an impaired internalisation and subsequent
degradation of EGFR in DiF62 cells.
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Figure 1. Growth response of parental cells and drug-resistant variants to doubling dilutions of anti-EGFR mAb ICR62 and gefitinib. Growth
response of DiFi parental cells and the drug-resistant variants DiFi62 and DiFiG cells to doubling dilutions of anti-EGFR mAb ICR62 (A) and
gefitinib (B).The cell surface expression of erbB family members measured by flow cytometry analysis in DiFi parental and its drug-resistant variants
DiFi62 and DiFiG cells (C). The expression of total EGFR in DiFi parental and its drug-resistant variants DiFi62 and DiFiG cells using a mouse anti-
EGFR antibody (F4) and rat anti-EGFR antibody ICR10 and ICR62 by western blotting and immunofluorescence (D), and basal levels of
phosphotyrosine and phosphorylated EGFR sites (E) by western blotting. Immunofluorescence staining of the EGFR in DiFi parental and its drug-
resistant variants DiFi62 and DiFiG cells following incubation with anti-EGFR mAbs ICR62 (200 nmol l 1), cetuximab (200nmol l1) for 1 h on ice or
37 1C (F). Internalised EGFR is indicated by the intracellular endocytic vesicles staining for EGFR as shown by the white arrows.
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Partial loss of EGFR gene is associated with resistance to anti-
EGFR mAb ICR62. On the basis of the above findings, we sought
to further investigate whether there were any genetic alterations
that had occurred as a consequence of chronic treatment with anti-
EGFR mAb ICR62 or small molecule TKI gefitinib in DiFi cells.
For this purpose, we performed mutational analysis by using Ion
Ampliseq cancer panel targeting 50 cancer hotspot genes, such as
KRAS, NRAS, BRAF, PIK3CA, EGFR, ErbB2, ErbB3, ErbB4 and
TP53. DNA sequencing revealed a missense mutation of C4G
substitution in chromosome 17 at nucleotide 97 of TP53 gene
causing a substitution of proline to alanine at amino acid 97 in
both DiFi62 and DiFiG drug-resistant variant cells (Table 2).
In addition, a synonymous mutation of A4G substitution in
chromosome 4 at nucleotide 858 of F-box and WD repeat domain
containing 7 (FBXW7) gene and a non-coding mutation
in chromosome 4 in the intronic region of KDR gene was
found in DiFiG and DiFi62 drug-resistant variants respectively
(Table 2). Interestingly, in DiFi62 drug-resistant variant cells, a
novel loss of copy number of 48.584 kb in length in the EGFR and
EGFR-AS1 genes corresponding to the regions encoding for the
intracellular domain of the EGFR protein was also detected, which
was not present in DiFi parental or DiFiG drug-resistant variant
cells (Table 2).
These findings further confirmed that the intracellular domain of
the EGFR is indeed altered causing diminished receptor internalisa-
tion and/or degradation and as a result DiFi62 drug-resistant variant
cells have an increased extracellular expression of EGFR.
Resistance to anti-EGFR mAb ICR62 is accompanied by
upregulation of pHER-2 and pHER-3. Having shown that
acquired resistance to anti-EGFR mAb ICR62 in DiFi cells is
accompanied by increased level of cell surface EGFR, but not that
of HER-2 or HER-3, we next examined whether the acquired
resistance to ICR62 was associated with increased activation of
HER-2, HER-3 and/or other alternative receptor tyrosine kinases
that activate overlapping signal transduction pathways down-
stream of EGFR. We performed a high-throughput comparative
analysis using a phosphor-RTK array kit measuring a panel of
phosphorylated RTKs in parental DiFi cells vs the resistant sublines
(Figure 2A and B). Of the phosphorylated RTKs measured, the
erbB family members were found to be phosphorylated in DiFi
parental cells and in DiFi62 and DiFiG cells (Figure 2A). As shown
in Figure 2A–C, resistance to ICR62 was accompanied by a
reduction in the level of pEGFR but increased phosphorylation of
both HER-2 and HER-3 in DiFi62 cells (Figure 2A and B). In
contrast, the phosphorylation of EGFR and HER-2 in DiFiG cells
remained the same while the phosphorylation of HER-3 appeared
to be lower compared with the findings in DiFi parental cells
(Figure 2A and B). As shown in Figure 2C, phosphorylation of
other RTKs in DiFi parental or its drug-resistant sublines was not
detectable using the RTK array kit. Taken together, these data
indicate that acquired resistance to ICR62 was accompanied by an
increased level of cell surface EGFR and increased phosphorylation
of both HER-2 and HER-3. We further validated the findings of the
RTK array kit by western blot analysis to measure the levels of
phosphorylated HER-2, and HER-3, as well as that of MAPK and
Akt, two major molecules mediating cell signal transduction
downstream of EGFR. The results of western blotting corroborate
with the findings from the phospho-RTK array (Figure 2C). The
increased phosphorylation of HER-2 and HER-3 in DiFi62 cells
relative to DiFi parental cells was accompanied by increased
phosphorylation of MAPK and Akt (Figure 2C). We also examined
the phosphorylation of several other downstream signal transduc-
tion pathways such as JAK/STAT, MET and Src family kinases.
Although no striking differences were noted in the activation of the
STATs (data not shown), there was an increased phosphorylation
of Src (Ser 17) but not MET phosphorylation in DiFi62 and DiFiG
cells compared with parental DiFi cells (Figure 2D).
ICR62-resistant DiFi cells acquire resistance to other anti-EGFR
mAbs but remain sensitive to small molecule HER inhibitors.
As acquired resistance to treatment with anti-EGFR mAbs would
lead to a short-term response, we next investigated response of
DiFi62 cells to treatment with other anti-EGFR mAbs including
mAb ICR61 and cetuximab (Modjtahedi et al, 1993b). It would be
interesting to determine whether some of these anti-EGFR mAbs
in our panel, which are directed against epitopes distinct from the
ICR62 binding site, would be effective in inhibiting the growth of
DiFi62 cells. As shown in Figure 3A, all three mAbs bind to the
extracellular domain of the EGFR in both parental DiFi cells and
its two sublines. As expected, parental DiFi cells were highly
sensitive to treatment with all anti-EGFR mAbs used in this study
(Figure 3B, Table 1). However, DiFi62 cells were found to acquire
resistance to treatment with either ICR61 or cetuximab
(Figure 3C). In contrast, DiFiG cells were sensitive to treatment
with either cetuximab or ICR62 but not as sensitive to ICR61
(Figure 3D, Table 1). Taken together, these results suggest that
acquired resistance in DiFi62 cells is not owing to an inability of
ICR62 and other antibodies to bind to the extracellular domain of
the EGFR in these cells.
ICR62-resistant DiFi cells remain sensitive to small molecule
HER inhibitors by inhibiting the HER-2/HER-3 phosphoryla-
tion. Having demonstrated that DiFi62 variant cells also acquire
resistance to treatment with other anti-EGFR antibodies and the
resistance was accompanied by increase in the levels of pHER-2
and pHER-3, we next examined the sensitivity of DiFi62 and
DiFiG cells to treatment with a panel of small molecule TKIs,
including the irreversible pan-HER inhibitors afatinib, canertinib,
and neratinib, the equipotent reversible pan-HER inhibitor
sapitinib, the reversible dual EGFR and HER-2 inhibitor lapatinib,
and several other TKIs including the Bcr-Abl inhibitor imatinib
and dual Bcr-Abl and Src inhibitor dasatinib, the Alk inhibitor
PF04217903 mesylate, and the dual cMet and Alk inhibitor
crizotinib. Of the HER-inhibitors, DiFi parental cells were highly
sensitive to the pan-HER inhibitors, in particular sapitinib and
afatinib (Figure 4A, Table 1). More importantly, drug-resistant
Table 2. Mutational analysis of DiFi62 and DiFiG drug-resistant variants normalised against DiFi parental cells
Sample Gene Genotype Amino Acid Comment P-value
DiFiG FBXW7 c.858A4G — An SNV causing a synonymous mutation at
transcript NM_033632.3
0.00001
TP53 c.97C4G Pro33Ala An SNV causing a missense mutation at
transcript NM_001276760.1
0.00001
DiFi62 KDR — — Non-coding mutation (NM_002253.2) 0.00001
TP53 c.97C4G Pro33Ala An SNV causing a missense mutation at
transcript NM_001276760.1
0.00001
EGFR, EGFR-AS1 7p11.2(55211044-55259628)x1 — 48.584 kb deletion CNV confidence¼12.67
Abbreviations: CNV¼ copy number variation; EGFR¼epidermal growth factor receptor; SNV¼ single-nucleotide variant.
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variant DiFi62 cells were equally sensitive to the pan-HER
inhibitors but not the reversible dual EGFR and HER-2 inhibitor
lapatinib (Figure 4B, Table 1). Although DiFiG cells showed a
marked decreased sensitivity to the other TKIs, they were found to
be relatively sensitive to treatment with the pan-HER inhibitors
neratinib, canertinib, sapitinib and afatinib (Figure 4C, Table 1).
We next examined the effects of these drugs on inhibiting
phosphorylation of EGFR and related proteins. We found that
compared with parental DiFi cells, treatment of DiFi62 cells with
ICR62 or cetuximab could not inhibit phosphorylation of
EGFR (represented by EGFR-Y1068), HER-2, HER-3 or MET,
nor phosphorylation of subsequent Akt and MAPK-mediated
downstream signalling pathways (Figure 4D). In contrast, the
irreversible pan-HER inhibitor afatinib was effective in inhibiting
the activity of EGFR, HER-2, HER-3, MET, Akt and MAPK in
DiFi62 cells. We found that the reversible EGFR TKI gefitinib was
equally effectively in inhibiting phosphorylation of HER-2, HER-3
and MET in parental DiFi, DiFi62 and DiFiG cells (Figure 4D).
Although the treatment with anti-EGFR mAbs ICR62 and
cetuximab or small molecule TKI gefitinib was able to modestly
reduce the activity of MAPK and MET, treatment with the
irreversible pan-HER inhibitor afatinib completely inhibited the
activity of MAPK but not MET in DiFiG cells (Figure 4D). No
difference was observed in the activity of Src following treatment
with the anti-EGFR mAbs or small molecule TKIs in parental DiFi
cells and in DiFi62 or DiFiG cells (Figure 4D). These results
suggest that HER-2 and HER-3 activation has an important role in
the manifestation of drug resistance to anti-EGFR mAb therapy in
DiFi62 cells.
DISCUSSION
As noted earlier, the human EGFR is an important therapeutic
target in a wide range of human cancers, and of the EGFR
inhibitors only the anti-EGFR mAbs cetuximab and panitumumab
have currently been approved for the treatment of patients with
metastatic colorectal cancer. However, development of drug
resistance to these agents, which is very common in many such
patients, is a major cause of treatment failure following
a short course of treatment (Modjtahedi and Essapen, 2009;
Misale et al, 2014). Although the role of EGFR and other HER
family members in regulating progression of many types of solid
tumours, including colorectal cancer, is well established, their roles
in the development of acquired drug resistance have not been
extensively studied (Khelwatty et al, 2013; Arteaga and Engelman,
2014). A few earlier studies have reported that acquired drug
resistance to anti-EGFR therapy in colorectal cancer, head and
neck squamous cell carcinoma and non-small cell lung cancer
models can be attributed to dysregulation of EGFR endocytosis,
upregulation of EGFR and transactivation of HER-2 and/or HER-3
(Lu et al, 2007; Wheeler et al, 2008; Yonesaka et al, 2011) and
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mutations on the extracellular domain of the EGFR or the
intracellular tyrosine kinase domain of the EGFR (Montagut et al,
2012; Arena et al, 2015).
In our current study, we developed resistant sublines and
investigated the mechanisms of acquired resistance to treatment with
the anti-EGFR mAb ICR62 and the EGFR TKI gefitinib in DiFi
colorectal cancer cells. We found an increased level of cell surface
EGFR in DiFi cells following the treatment with chronic doses of the
anti-EGFR mAb ICR62 (Figure 1C). One reason for such an alteration
in the expression level of the EGFR could be owing to dysregulated
endocytosis and degradation (Wheeler et al, 2008). Earlier studies
indicated that EGFR endocytosis and degradation is regulated by the
process of ubiquitination where phosphorylated Cbl proteins bind to
EGFR either directly at phosphorylated residue 1045 or indirectly to
phosphorylated residue 1068 via adaptor protein Grb2 (Levkowitz et al,
1999; Waterman et al, 2002). Although alterations in the kinase domain
of EGFR are usually attributed to acquired drug resistance to TKI
therapy, in this study, for the first time to our knowledge, we provide
evidence that alteration in the intracellular domain of the EGFR may be
also associated with development of resistance to EGFR antibody-based
therapy. We found that in DiFi62 cells, the phosphorylation sites of the
EGFR, in particular Y1045 and Y1068, were predominantly
undetectable or markedly diminished compared with that in parental
DiFi cells (Figure 1E). This observation strongly suggests that increased
level of cell surface EGFR in DiFi62 cells may be caused, in part, by
dysregulated receptor internalisation and/or degradation (Figure 1F) as
a result of alterations in the tyrosine kinase domain of the EGFR. In
addition, the data from DNA sequencing of the DiFi62 drug-resistant
variant cells revealed a gene copy number variation lacking 48.584kb in
chromosome 7p11.2 55211044-55259628, which corresponds to the
region encoding for the intracellular domain of the EGFR protein
(Ekstrand et al, 1992; Kumar et al, 2008; Cho et al, 2011; Table 2).
Although many studies have investigated and reported the role of
gene copy number variations as a predictive biomarker for
response to anti-EGFR therapies in cancer, to our knowledge, its
relationship with acquired drug-resistance in colorectal cancer
has not been previously reported (Algars et al, 2011; Shen et al,
2014). Moreover, this finding could provide further explanation
for the lack of detection of ‘fast-migrating’ EGFR band by
mAb F4, which is detected by mAb ICR10, and lack of detection
of several EGFR autophosphorylation sites in this study
(Figure 1D–E).
In a recent study, Montagut et al found that acquired resistance
of DiFi cells to cetuximab is owing to emergence of a mutation in
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the EGFR extracellular domain (S492R) that prevents the binding
of cetuximab to the EGFR. Interestingly, they also reported that
cells with such mutation retained binding to and were growth
inhibited by panitumumab (Montagut et al, 2012). More recently,
Arena et al have reported the emergence of a complex pattern of
mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes in
cetuximab-resistant colorectal cancer including multiple mutations
in the EGFR extracellular domain (K467T, R451C, G465R, S464L
and I491M). Of these, with the exception of R451C mutated cells,
cells containing other mutations were incapable of binding with
cetuximab, while panitumumab was able to bind to only a subset of
EGFR mutant cells (K467T and R451C) (Arena et al, 2015). In this
study, we show that both ICR62 and cetuximab bind equally well
to both parental DiFi cells and their ICR62 variants (DiFi62;
Figure 3A). Indeed, when treated with cetuximab, which binds to
different epitopes on the EGFR extracellular domain, DiFi62 cells
maintained EGFR, HER2 and HER-3 activities, as well as Akt- and
MAPK-mediated signalling (Figure 4D). In contrast, when treated
with small molecule TKIs, such as irreversible pan-HER inhibitor
afatinib, DiFi62 exhibited not only reduced phosphorylation of
EGFR, HER-2 and HER-3, but also reduced Akt- and MAPK-
mediated cell signalling (Figure 4D). These findings also provide an
explanation to the higher sensitivity of DiFi62 cells to pan-HER
inhibitors compared with mono or dual inhibitors of EGFR or
EGFR/HER2, such as lapatinib, used in this study (Figures 3B and
4B). In addition, as inhibition of HER-2 or downstream pathways
may lead to transcriptional and posttranslational upregulation of
HER-3, dual inhibition of EGFR and HER-2 with lapatinib does
not eliminate the compensatory upregulation of HER-3 (Garrett
et al, 2013). Therefore, our results suggest that increased activation
of HER-3 signalling could be a major contributing factor by which
colorectal cancer could acquire resistance to treatment with anti-
EGFR antibody ICR62 or cetuximab. As evidence supporting this
speculation, we found DiFi62 and DiFiG cells remain sensitive to
treatment with small molecules and in particular pan-HER
inhibitors (Figure 4A and B).
Previous studies in other models have shown that increased
levels of EGFR could lead to transactivation of HER-2 and HER-3
(Wheeler et al, 2008; Brand et al, 2013). In this study, we have
found that acquired resistance to the anti-EGFR antibody ICR62 in
colorectal cancer cells was accompanied by an increased level
of cell surface EGFR and increased activation of pHER-2 and
pHER-3, which was accompanied by increased phosphorylation of
MAPK and Akt in DiFi62 cells. Our result would therefore support
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that HER-2/HER-3 phosphorylation has a major role in driving the
survival and proliferation of DiFi62 cells (Yonesaka et al, 2011).
Other reports also suggest that HER-3 has an important role in the
regulation of response to anti-EGFR therapies. For example, in a
recent study, cetuximab-resistant head and neck cancer cells were
found to escape treatment by anti-EGFR therapy through HER-3
activation (Kjaer et al, 2013). Similarly, in another study,
heregulin-EGFR-HER-3 autocrine signalling axis was found to
mediate acquired resistance to lapatinib in HER-2-positive breast
cancer models (Xia et al, 2013). More recently, HER-3 phosphor-
ylation in colorectal cancer cells was shown to be strictly dependent
on association with HER-2, and that HER-2/HER-3 signalling
reversed the effect of EGFR blockade on inhibiting colorectal
cancer cell growth (Zhang et al, 2014). Taken together, these
studies suggest that HER-3 mediates tumour response to anti-
EGFR therapy and activation of HER-3 signalling may help cells to
evade the antitumour effects of anti-EGFR mAbs, such as ICR62
and/or cetuximab.
Many previous studies also suggest that MET and Src non-
receptor tyrosine kinase have a role in the mechanism of resistance to
anti-EGFR mAb therapies (Lu et al, 2007; Liska et al, 2011; Song et al,
2014). However, while we found an increase in the phosphorylation
of Src in both DiFi62 and DiFiG cells compared with DiFi parental
cells, we did not find significant changes in the levels of MET
activation in these cells (Figure 3D). In addition, we found no
significant differences in the growth of DiFi parental and DiFi62 or
DiFiG cells when treated with dasatinib, a Bcr-Abl and Src dual
inhibitor, or crizotinib, a cMet and Alk dual inhibitor (Figure 4A–C).
In conclusion, our results demonstrate that acquired resistance
of colorectal tumour cells to treatment with anti-EGFR mAb
ICR62 is accompanied by an increased level of cell surface EGFR,
and upregulation of pHER-2/pHER-3. We demonstrated that the
colorectal cancer cells that acquire resistance to ICR62 also acquire
resistance to treatment with other anti-EGFR mAbs such as
cetuximab, but remain highly sensitive to treatment with small
molecule pan-HER inhibitors. Our results provide a rationale for
further investigation on the therapeutic potential of the pan-HER
family inhibitors in the treatment of colorectal cancer with
acquired resistance to EGFR blocking antibodies.
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